Skip to main content
Equibles
LSTA logo

LSTA · Lisata Therapeutics, Inc. · Metrics

Track LSTA — free

Use LSTA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LSTA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.64 -0.26 (-13.68%) At close · Sep 10
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our current business plan and existing capital resources, management has concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of twelve months from the date of issuance of the accompanying consolidated financial statements.”
View the 10-Q filed Aug 6, 2026
Market Cap
$14.78M
Shares
9.01M

LSTA metrics

61 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.64
Market cap
$14.78M

Price action

20 metrics
Price change (1W)
+21.0%
Price change (30D)
+57.0%
Price change (3M)
-47.4%
Price change (6M)
-62.2%
Price change (YTD)
+2.2%
Price change (1Y)
-13.6%
Trailing year
Price change (5Y)
—
52-week high
$5.04
52-week low
$0.99
Change from 52-week high
-62.3%
Change from 52-week low
+91.9%
Annualized volatility
126.8%
Annualized volatility (3M)
145.0%
Beta
0.7
RSI (14D)
59.5
Price vs SMA 50
-4.8%
Price vs SMA 200
-39.2%
Avg volume (3M)
238,431
Relative volume
0.9
Average dollar volume
$433,941

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
9.01M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
171.2×
reciprocal yield 0.6%
P / book
2.1
reciprocal yield 48.2%
FCF yield
-72.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-85.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-06

Profitability

9 metrics
Gross margin
—
Operating margin
-16,428.0%
Trailing 12 months
Net margin
-14,621.0%
Gross profit (TTM)
$1.72M
Operating profit (TTM)
−$16.43M
Net income (TTM)
−$14.62M
Trailing 12 months
Diluted EPS (TTM)
$-1.64
FCF margin
-12,323.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.68

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$100,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-177.4%
Return on assets
-132.6%
Debt / equity
—
Current ratio
3.7
EBITDA (TTM)
−$16.36M
Free cash flow (TTM)
−$12.32M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$10.44M
Total assets
$11.03M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$12.32M
Capital expenditures (TTM)
$0
R&D (TTM)
$4.88M
SG&A (TTM)
$12.09M
Stock compensation (TTM)
$1.03M
R&D / revenue
4,882.0%
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
32
13F filer change QoQ
-3
Institutional ownership
12.1%

Short interest

3 metrics
Short interest
1.6%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
50 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 320017 CUSIP 128058302 13F (30d) 21 filings 21 filers Visit website Investor relations